We envisage therapeutic scenarios where cancer patients are treated with IFN-DC either as unloaded antigen-presenting cells injected intratumorally [57] or as in vitro antigen loaded DC, and subsequently injected with anti-PD1 antibodies or other ICI to increase the antitumor response in selected combination therapies (Figure 3). Here, IFNA1 is linked to cancer.